Boston Scientific Q2 FY25: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 1, 2025
Revenue$5.06B
+23% year over year
Gross profit$3.42B
68% margin
Operating profit$0.82B
16% margin
Net profit$0.80B
16% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.06 | 100% | +23% |
| Electrophysiology | 0.84 | 17% | +96% |
| Global endoscopy | 0.74 | 14% | +9% |
| Interventional cardiology | 0.73 | 14% | +10% |
| Peripheral interventions | 0.70 | 14% | +18% |
| Urology & pelvic health | 0.68 | 13% | +29% |
| Cardiac rhythm management | 0.59 | 12% | +2% |
| Watchman | 0.49 | 10% | +28% |
| Neuromodulation | 0.30 | 6% | +7% |
| Cost of revenue | −1.64 | 32% | |
| Gross profit | 3.42 | 68% margin | −2pp |
| SG&A | −1.72 | 34% | −1pp |
| Other | −0.89 | 17% | +0pp |
| Operating profit | 0.82 | 16% margin | +4pp |
| Other income, net | 0.12 | ||
| Tax | −0.15 | ||
| Net profit | 0.80 | 16% margin | +8pp |
182 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest